Edwards Historical Income Statement

EW Stock

USD 70.48 0.10 0.14%

Historical analysis of Edwards Lifesciences income statement accounts such as Selling General Administrative of 1.8 B can show how well Edwards Lifesciences Corp performed in making a profits. Evaluating Edwards Lifesciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Edwards Lifesciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Edwards Lifesciences Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Edwards Lifesciences Corp is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

About Edwards Income Statement Analysis

Edwards Lifesciences Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Edwards Lifesciences shareholders. The income statement also shows Edwards investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Edwards Lifesciences Income Statement Chart

At this time, Edwards Lifesciences' Income Before Tax is fairly stable compared to the past year. Total Other Income Expense Net is likely to climb to about 67.2 M in 2024, whereas Interest Expense is likely to drop slightly above 10.6 M in 2024.

Selling General Administrative Total Revenue Other Operating Expenses Net Income From Continuing Ops

Total Revenue

Total revenue comprises all receipts Edwards Lifesciences Corp generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Edwards Lifesciences Corp. It is also known as Edwards Lifesciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Edwards Lifesciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Edwards Lifesciences Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

	2021	2022	2023	2024 (projected)
Gross Profit	4.0B	4.3B	4.6B	4.9B
Total Revenue	5.2B	5.4B	6.0B	6.3B

Gross Profit Total Revenue

Edwards Lifesciences income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation	Extraordinary Items	Selling And Marketing Expenses
Depreciation And Amortization		0.87	0.65	0.7	0.7	0.68	0.75	0.7	0.7	0.74	0.85	0.67	0.69	-0.05	0.75	0.13	0.85	0.3	0.75	0.13	0.51	0.19	0.72	0.8	0.41
Interest Expense	0.87		0.74	0.73	0.74	0.73	0.77	0.6	0.74	0.63	0.77	0.73	0.78	0.21	0.81	0.23	0.87	0.08	0.62	0.05	0.53	0.21	0.73	0.71	0.46
Selling General Administrative	0.65	0.74		0.99	0.99	0.99	0.93	0.87	0.99	0.85	0.76	1.0	0.93	-0.03	0.95	0.25	0.84	0.26	0.84	0.26	0.86	0.65	0.83	0.84	0.73
Total Revenue	0.7	0.73	0.99		1.0	1.0	0.95	0.91	1.0	0.9	0.81	0.99	0.92	-0.09	0.95	0.23	0.85	0.34	0.89	0.28	0.86	0.64	0.84	0.87	0.71
Gross Profit	0.7	0.74	0.99	1.0		1.0	0.95	0.91	1.0	0.9	0.8	1.0	0.92	-0.09	0.95	0.24	0.86	0.33	0.88	0.29	0.85	0.63	0.85	0.87	0.73
Other Operating Expenses	0.68	0.73	0.99	1.0	1.0		0.93	0.89	1.0	0.88	0.79	1.0	0.91	-0.07	0.95	0.21	0.84	0.32	0.88	0.27	0.88	0.67	0.83	0.87	0.71
Operating Income	0.75	0.77	0.93	0.95	0.95	0.93		0.86	0.95	0.86	0.81	0.93	0.87	-0.08	0.89	0.27	0.82	0.4	0.83	0.33	0.77	0.47	0.83	0.83	0.66
Ebit	0.7	0.6	0.87	0.91	0.91	0.89	0.86		0.9	1.0	0.79	0.88	0.79	-0.44	0.84	0.08	0.79	0.56	0.86	0.29	0.71	0.49	0.77	0.85	0.61
Research Development	0.7	0.74	0.99	1.0	1.0	1.0	0.95	0.9		0.89	0.8	1.0	0.91	-0.09	0.95	0.21	0.85	0.35	0.89	0.27	0.86	0.64	0.84	0.88	0.72
Ebitda	0.74	0.63	0.85	0.9	0.9	0.88	0.86	1.0	0.89		0.81	0.87	0.78	-0.44	0.84	0.09	0.8	0.56	0.86	0.28	0.67	0.44	0.76	0.86	0.58
Cost Of Revenue	0.85	0.77	0.76	0.81	0.8	0.79	0.81	0.79	0.8	0.81		0.77	0.75	-0.15	0.78	0.27	0.89	0.37	0.76	0.22	0.56	0.33	0.72	0.81	0.44
Total Operating Expenses	0.67	0.73	1.0	0.99	1.0	1.0	0.93	0.88	1.0	0.87	0.77		0.92	-0.05	0.95	0.23	0.84	0.3	0.87	0.27	0.87	0.67	0.84	0.85	0.74
Income Before Tax	0.69	0.78	0.93	0.92	0.92	0.91	0.87	0.79	0.91	0.78	0.75	0.92		0.21	0.98	0.5	0.92	-0.01	0.71	0.4	0.72	0.48	0.83	0.74	0.68
Total Other Income Expense Net	-0.05	0.21	-0.03	-0.09	-0.09	-0.07	-0.08	-0.44	-0.09	-0.44	-0.15	-0.05	0.21		0.11	0.53	0.1	-0.87	-0.3	0.09	-0.04	-0.07	0.03	-0.24	0.04
Net Income	0.75	0.81	0.95	0.95	0.95	0.95	0.89	0.84	0.95	0.84	0.78	0.95	0.98	0.11		0.33	0.94	0.1	0.79	0.27	0.76	0.51	0.87	0.83	0.7
Income Tax Expense	0.13	0.23	0.25	0.23	0.24	0.21	0.27	0.08	0.21	0.09	0.27	0.23	0.5	0.53	0.33		0.37	-0.53	-0.11	0.77	0.03	-0.03	0.19	-0.11	0.16
Net Income From Continuing Ops	0.85	0.87	0.84	0.85	0.86	0.84	0.82	0.79	0.85	0.8	0.89	0.84	0.92	0.1	0.94	0.37		0.09	0.72	0.23	0.61	0.32	0.86	0.8	0.61
Non Recurring	0.3	0.08	0.26	0.34	0.33	0.32	0.4	0.56	0.35	0.56	0.37	0.3	-0.01	-0.87	0.1	-0.53	0.09		0.57	-0.13	0.3	0.19	0.2	0.52	0.12
Non Operating Income Net Other	0.75	0.62	0.84	0.89	0.88	0.88	0.83	0.86	0.89	0.86	0.76	0.87	0.71	-0.3	0.79	-0.11	0.72	0.57		0.04	0.85	0.66	0.72	0.97	0.63
Tax Provision	0.13	0.05	0.26	0.28	0.29	0.27	0.33	0.29	0.27	0.28	0.22	0.27	0.4	0.09	0.27	0.77	0.23	-0.13	0.04		0.18	0.14	0.27	-0.08	0.29
Net Interest Income	0.51	0.53	0.86	0.86	0.85	0.88	0.77	0.71	0.86	0.67	0.56	0.87	0.72	-0.04	0.76	0.03	0.61	0.3	0.85	0.18		0.89	0.75	0.74	0.86
Interest Income	0.19	0.21	0.65	0.64	0.63	0.67	0.47	0.49	0.64	0.44	0.33	0.67	0.48	-0.07	0.51	-0.03	0.32	0.19	0.66	0.14	0.89		0.43	0.5	0.72
Reconciled Depreciation	0.72	0.73	0.83	0.84	0.85	0.83	0.83	0.77	0.84	0.76	0.72	0.84	0.83	0.03	0.87	0.19	0.86	0.2	0.72	0.27	0.75	0.43		0.73	0.8
Extraordinary Items	0.8	0.71	0.84	0.87	0.87	0.87	0.83	0.85	0.88	0.86	0.81	0.85	0.74	-0.24	0.83	-0.11	0.8	0.52	0.97	-0.08	0.74	0.5	0.73		0.53
Selling And Marketing Expenses	0.41	0.46	0.73	0.71	0.73	0.71	0.66	0.61	0.72	0.58	0.44	0.74	0.68	0.04	0.7	0.16	0.61	0.12	0.63	0.29	0.86	0.72	0.8	0.53

Click cells to compare fundamentals

Edwards Lifesciences Account Relationship Matchups

Edwards Lifesciences income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	183.8M	135.4M	163.3M	166.8M	144.9M	89.7M
Interest Expense	20.7M	15.8M	18.4M	19.2M	17.6M	10.6M
Selling General Administrative	1.2B	1.2B	1.5B	1.6B	1.8B	1.8B
Total Revenue	4.3B	4.4B	5.2B	5.4B	6.0B	6.3B
Gross Profit	3.2B	3.3B	4.0B	4.3B	4.6B	4.9B
Other Operating Expenses	3.1B	3.1B	3.6B	3.6B	4.3B	4.5B
Operating Income	1.1B	1.6B	1.3B	1.7B	1.5B	1.6B
Ebit	1.1B	938.9M	1.7B	1.8B	1.5B	1.6B
Research Development	752.7M	760.7M	903.1M	945.2M	1.1B	1.1B
Ebitda	1.3B	1.1B	1.9B	2.0B	1.5B	1.6B
Cost Of Revenue	1.1B	1.1B	1.2B	1.1B	1.4B	697.9M
Total Operating Expenses	2.0B	2.0B	2.4B	2.5B	2.9B	3.0B
Income Before Tax	1.2B	916.7M	1.7B	1.8B	1.6B	1.7B
Total Other Income Expense Net	19.7M	19.1M	11.7M	18.9M	64M	67.2M
Net Income	1.0B	823.4M	1.5B	1.5B	1.4B	1.5B
Income Tax Expense	119.6M	93.3M	198.9M	245.5M	198.7M	113.1M
Net Income Applicable To Common Shares	1.0B	823.4M	1.5B	1.5B	1.8B	1.8B
Net Income From Continuing Ops	1.0B	823.4M	1.5B	1.5B	1.4B	836.3M
Non Recurring	98M	405.4M	20.6M	76.5M	88.0M	92.4M
Non Operating Income Net Other	40.4M	34.9M	30.1M	38.1M	43.8M	46.0M
Tax Provision	119.6M	93.3M	198.9M	245.5M	207.6M	201.8M
Net Interest Income	11.5M	7.6M	(1M)	16.3M	40.7M	42.7M
Interest Income	32.2M	7.6M	1M	16.3M	67.2M	70.6M
Reconciled Depreciation	89.3M	107.2M	134.8M	139.6M	143.6M	121.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Edwards Historical Income Statement

About Edwards Income Statement Analysis

Edwards Lifesciences Income Statement Chart

Total Revenue

Other Operating Expenses

Edwards Lifesciences income statement Correlations

Edwards Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Edwards Lifesciences income statement Accounts

Also Currently Popular

Additional Tools for Edwards Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Selling General Administrative
Gross Profit	+ 1.0	Total Revenue
Other Operating Expenses	+ 1.0	Total Revenue
Research Development	+ 1.0	Total Revenue
Other Operating Expenses	+ 1.0	Gross Profit
Research Development	+ 1.0	Gross Profit

Non Recurring	- 0.87	Total Other Income Expense Net
Non Recurring	- 0.53	Income Tax Expense
Total Other Income Expense Net	- 0.44	Ebitda
Total Other Income Expense Net	- 0.44	Ebit
Non Operating Income Net Other	- 0.3	Total Other Income Expense Net
Extraordinary Items	- 0.24	Total Other Income Expense Net